CompletedNot Applicable

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

United States30 participantsStarted 2021-08-16

Plain-language summary

More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Insulin-treated patients with DM2 (treated with basal-bolus insulin regimens (MDI), ± non-insulin medications) and Uncontrolled glycemic control Exclusion Criteria: * History of type 1 DM (DM1) * Pregnant Patients * Extensive skin changes/disease or allergies that preclude wearing the CGM sensor * Subjects who have end-stage renal disease requiring dialysis * Significant psychiatric illness or any other condition rendering the subject incapable of understanding the objectives and potential consequences of the study

What they're measuring

Change in Hyperglycemia (Percent Change in HbA1c)

Timeframe: 3 months

Trial details

NCT IDNCT04800471

SponsorUniversity of Maryland, Baltimore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-09

Results submitted2025-10-20

View on ClinicalTrials.gov More Diabetes Mellitus trials